News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
PRECOS Announces World Pharma Congress 2013 Co-Presentation With Crown Bioscience, Inc. Illustrating the Benefits of Clinically Relevant PDX Models for Oncology Drug Discovery
11/1/2013 11:08:30 AM
LOUGHBOROUGH, UK, 19th July 2013 - Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology, today announced the availability of its co-presentation with Crown Bioscience from the World Pharma Congress 2013 2nd Annual Meeting on Predictive Preclinical Models in Oncology - Challenging Cancer Heterogeneity with Reproducible and Predictive Preclinical Studies. The presentation highlights the largest comprehensive panel of PDX (Patient-Derived Xenograft) models of cancer which better predict how the drug is likely to behave in clinical trials. The new presentation is available for download free of charge via www.precos.co.uk/publications/ or email firstname.lastname@example.org to request a copy.
Entitled LION™, PUMA™ and The Tumour Microenvironment: Building Clinical Relevant PDX models for Oncology Drug Discovery and authored by Dr Aaron Cranston, Head of In vivo Services at PRECOS Ltd, the presentation discusses PRECOS’ most recent innovations in oncology drug discovery and partnership with Crown Biosciences. The presentation highlights the expertise and offerings, as providers of the largest panel of PDX models for drug discovery and the largest panel of Caucasian (LIONTM) and Asian NSCLC PDX models. It addresses the molecular profiling and characterization that underpins the models and how PRECOS builds PDX models of resistance to reflect the clinical situation. The presentation is suitable for scientists looking to fast-track new agents into the clinic through innovative approaches.
Dr Aaron Cranston, Head of In vivo Services, PRECOS Ltd comments, “We were delighted to present at the World Pharma Congress this year, sharing some of the unique clinically relevant models that PRECOS has developed, such as LIONTM ADC and SCC subset models and PUMA™ unique models of acquired resistance. These innovations are significant and have been particularly well received. Addressing scientists’ current needs for models that mirror the clinical population and which reflect the patient situation for each aspect of cancer progression heavily influences the development of our platforms. We’re passionate about helping fast forward drug discovery programs.”
PRECOS has an established track record in providing expert support to direct cancer drug development projects from concept to clinic. Dr Aaron Cranston also chaired a session on “Addressing Inter-Patient Response Heterogeneity in Predictive Preclinical Models of Oncology” and discussed the latest news of PRECOS’ collaboration to provide over 150 characterised NSCLC models for Avatar trials. PRECOS is committed to evaluating the innovative cancer medicines of the future in patient-relevant models to ensure that pre-clinical efficacy assessment is predictive of how a therapeutic is likely to behave in clinical trials with cancer patients.
The World Pharma Congress, now in its twelfth consecutive, was hosted at Lowes Philadelphia Hotel in Philadelphia from 4th – 6th June 2013. The congress was attended by international scientists and researchers and covered the latest preclinical strategies and technologies for driving better predictions and the latest innovations in oncology drug discovery.
For further information and to hear more about PRECOS’ innovations, please call +44 (0)870 166 6234, email email@example.com or visit www.precos.co.uk.
About PRECOS Ltd
PRECOS Ltd. is a flexible pre-clinical research and development service with a specific focus on oncology, with an established track record in providing expert support to direct cancer drug development projects from concept to clinic. PRECOS evaluates the innovative cancer medicines of the future in patient-relevant models to ensure that pre-clinical efficacy assessment is predictive of how the drug is likely to behave in clinical trials with cancer patients. The PRECOS team of expert scientists assist in the selection and execution of appropriate analytical systems by a staged approach of in vitro studies, in vivo model development, subsequent in vivo mechanistic and therapeutic evaluations and post-study analyses, all conveyed with added value through specialist scientific interpretation of the data. PRECOS scientists apply cutting-edge technology and ideas to individual research programmes and delivers a flexible, tailored approach to all research objectives, whether a one-off service or a complete research programme.
PRECOS, an acronym of Pre-Clinical Oncology Services, was officially launched as a specialist business unit of the University of Nottingham (UK) in 2004. PRECOS evolved from the research expertise of the Division of Pre-clinical Oncology (formerly Academic Unit of Cancer Studies), which had successful collaborations with pharmaceutical and biotech companies in the UK, EU, US and Japan for over a decade. For further information: www.precos.co.uk
For further press information please contact: Sarah Morley - The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, United Kingdom. Tel: + 44 1477 539 539 Fax: +44 1477 539 540 E-mail: firstname.lastname@example.org
Help employers find you! Check out all the jobs and post your resume.